← Back to Search

Unified Protocol for Transdiagnostic Treatment of Emotional Disorders for Misophonia

N/A
Waitlist Available
Led By Zachary Rosenthal, Ph.D.
Research Sponsored by Duke University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up assessed weekly, up to 24 weeks
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing two psychological treatments, the Unified Protocol and process-based therapy, to help people with Misophonia. These treatments aim to teach skills that can reduce the distress and difficulties caused by Misophonia. The study will also check if these treatments are acceptable and practical for patients.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~assessed weekly, up to 24 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and assessed weekly, up to 24 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of patients that are satisfied with treatment as measured by the credibility and expectancy questionnaire (CEQ)
Number of patients who indicate treatment was acceptable to them (i.e., the treatment approach made sense and was perceived as reasonable)
Secondary study objectives
Change in anger as measured by the Clinical Anger Scale
Change in anxiety as measured by the Overall Anxiety Severity and Impairment Scale
Change in depression as measured by the Overall Depression Severity and Impairment Scale
+2 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

4Treatment groups
Experimental Treatment
Group I: Unified Protocol, 4 week baselineExperimental Treatment1 Intervention
Participants in this arm will complete four weeks of baseline assessment (during which they will complete questionnaires but not start treatment) and then receive 16 sessions of the Unified Protocol (UP). The UP is an emotion-focused treatment designed to teach participants skills to help manage difficult experiences.
Group II: Unified Protocol, 2 week baselineExperimental Treatment1 Intervention
Participants in this arm will complete two weeks of baseline assessment (during which they will complete questionnaires but not start treatment) and then receive 16 sessions of the Unified Protocol (UP). The UP is an emotion-focused treatment designed to teach participants skills to help manage difficult experiences.
Group III: Process-based treatment, 4 week baselineExperimental Treatment1 Intervention
Participants in this arm will complete four weeks of baseline assessment (during which they will complete questionnaires but not start treatment) and then receive 16 sessions of the process-based therapy. Process-based therapy is a flexible therapy designed to teach skills that help people manage difficult experiences. Patient and therapist work together to determine which skills will be utilized.
Group IV: Process-based treatment, 2 week baselineExperimental Treatment1 Intervention
Participants in this arm will complete two weeks of baseline assessment (during which they will complete questionnaires but not start treatment) and then receive 16 sessions of the process-based therapy. Process-based therapy is a flexible therapy designed to teach skills that help people manage difficult experiences. Patient and therapist work together to determine which skills will be utilized.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Unified Protocol for Transdiagnostic Treatment of Emotional Disorders
2020
N/A
~110
Process-based Cognitive Behavioral Therapy
2020
N/A
~20

Find a Location

Who is running the clinical trial?

Duke UniversityLead Sponsor
2,451 Previous Clinical Trials
3,067,058 Total Patients Enrolled
3 Trials studying Misophonia
137 Patients Enrolled for Misophonia
Zachary Rosenthal, Ph.D.Principal InvestigatorDuke University
1 Previous Clinical Trials
39 Total Patients Enrolled
~2 spots leftby Nov 2025